Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 801–900 of 1,025
Parravano, M., Oddone, F., Tedeschi, M., Chiaravalloti, A., Perillo, L., Boccassini, B., & Varano, M. (2010) · Retina · doi:10.1097/iae.0b013e3181cfd3c6 · Cited by 53
Hollanders, K., Bergen, T. V., Kindt, N., Castermans, K., Leysen, D. C., Vandewalle, E., Moons, L., & Stalmans, I. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15681 · Cited by 55
Hikichi, T., Ohtsuka, H., Higuchi, M., Matsushita, T., Ariga, H., Kosaka, S., Matsushita, R., & Takami, K. (2010) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.05.026 · Cited by 51
Singer, M. A., Herro, A. M., Probandarwalla, S. S., Pollard, J., Amir, A., Herro, & Singer (2011) · Clinical ophthalmology · doi:10.2147/opth.s15028 · Cited by 51
“Ranibizumab has been shown to improve visual acuity by three lines in 30%–40% of patients with monthly dosing.(7) Bevacizumab has been shown to be equivalent to Ranibizumab with monthly dosing.”
BackgroundRanibizumab: A Review of Its Use in the Treatment of Neovascular Age-Related Macular Degeneration
Frampton, J. E. (2013) · Drugs & Aging · doi:10.1007/s40266-013-0077-9 · Cited by 54
“were considered legally blind) at 1 [33, 35] and 2 [34, 35] years (p B 0.”
BackgroundInfluentialSurgery for CNV and autologous choroidal RPE patch transplantation: exposing the submacular space
Cereda, M. G., Parolini, B., Bellesini, E., & Pertile, G. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1201-8 · Cited by 55
Diabetic Retinopathy and Age-Related Macular Degeneration in the U.S
Gibson, D. M. (2012) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2012.02.028 · Cited by 57
Semeraro, F., Morescalchi, F., Duse, S., Gambicorti, E., Romano, M. R., & Costagliola, C. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.911284 · Cited by 49
Nesmith, B. L. W., Ihnen, M. A., & Schaal, S. (2014) · Retina · doi:10.1097/iae.0000000000000247 · Cited by 55
Eleftheriadou, M. I., Vázquez-Alfageme, C., Citu, M. C., Crosby‐Nwaobi, R., Sivaprasad, S., Hykin, P. G., HAMILTON, R. D., & Patel, P. J. (2016) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2016.09.038 · Cited by 53
Roberts, P. K., Nesper, P. L., Gill, M. K., & Fawzi, A. A. (2016) · Retina · doi:10.1097/iae.0000000000001400 · Cited by 51
Hackett, S. F., Fu, J., Kim, Y. C., Tsujinaka, H., Shen, J., Silva, R. L. E., Khan, M., Hafiz, Z., Wang, T., Shin, M. D., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119935 · Cited by 51
“Clinical trials in patients with choroidal NV due to AMD demonstrated that monthly injections of ranibizumab, an antigen binding fragment that neutralizes all isoforms and fragments of VEGF-A, reduced fluid under or within the retina and improved vision (36, 37).”
BackgroundResultMantel, I. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.3.6 · Cited by 51
Evaluation of Pain in Intravitreal Bevacizumab Injections
Moisseiev, E., Regenbogen, M., Bartfeld, Y., & Barak, A. (2012) · Current Eye Research · doi:10.3109/02713683.2012.681335 · Cited by 51
Williams, T. A., & Blyth, C. P. (2011) · Eye · doi:10.1038/eye.2011.224 · Cited by 50
Fukuda, Y., Sakurada, Y., Matsubara, M., Hasebe, Y., Sugiyama, A., Kikushima, W., & Kashiwagi, K. (2021) · Biomedicines · doi:10.3390/biomedicines9091164 · Cited by 51
“Polypoidal choroidal vasculopathy (PCV), a variant of type 1 neovascularization secondary to neovascular age-related macular neovascularization (AMD), is characterized by aneurysmal dilation with or without branching vascular networks on indocyanine green angiography (ICGA) [1,2].”
BackgroundInfluentialInitial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD)
Otsuji, T., Sho, Tsumura, Koike, Tsuda, Nishimura, Takahashi, Y., & Nagaĭ (2013) · Clinical ophthalmology · doi:10.2147/opth.s46317 · Cited by 55
Scheduled versus Pro Re Nata Dosing in the VIEW Trials
Richard, G. W., Monés, J., Wolf, S., Korobelnik, J. F., Guymer, R. H., Goldstein, M., Norenberg, C., Sandbrink, R., & Zeitz, O. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.08.014 · Cited by 51
Cheung, C. M. G., Bhargava, M., Laude, A., Koh, A. C., Xiang, L., Wong, D., Niang, T., Lim, T. H., Gopal, L., & Wong, T. Y. (2012) · Clinical and Experimental Ophthalmology · doi:10.1111/j.1442-9071.2012.02765.x · Cited by 50
Tano, Y., & Ohji, M. (2010) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01843.x · Cited by 50
“In addition, the incidences of nonocular AEs suspected to be related to ranibizumab and AEs potentially related to systemic VEGF inhibition were also within the acceptable range and consistent with the earlier studies (Brown et al. 2006; Rosenfeld et al. 2006).”
BackgroundResultInfluentialFramme, C., Panagakis, G., & Birngruber, R. (2010) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.09-4496 · Cited by 52
Saito, M., Kano, M., Itagaki, K., Oguchi, Y., & Sekiryu, T. (2014) · Retina · doi:10.1097/iae.0000000000000236 · Cited by 51
the Action on AMD group, Amoaku, W. M. K., Blakeney, S. L., Freeman, M., Gale, R. P., Johnston, R., Kelly, S. P., McLaughlan, B., Sahu, D., & Varma, D. (2012) · Eye · doi:10.1038/eye.2011.343 · Cited by 51
Gelişken, F., Ziemssen, F., Voelker, M., Bartz‐Schmidt, K. U., & INHOFFEN, W. (2008) · Eye · doi:10.1038/sj.eye.6703098 · Cited by 50
Clinical safety of ranibizumab in age-related macular degeneration
Schmidt-Erfurth, U. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903418422 · Cited by 51
“Brown, 2006 [18] ANCHOR (1 year) Any arterial thromboembolic event* PDT: 3/143 (2.”
BackgroundMethodInfluentialThe eye as a model of ageing in translational research – Molecular, epigenetic and clinical aspects
Pathai, S., Shiels, P. G., Lawn, S. D., Cook, C., & Gilbert, C. E. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.11.002 · Cited by 54
Lee, J. H., & Lee, W. K. (2015) · Retina · doi:10.1097/iae.0000000000000809 · Cited by 50
“Intravitreal administration of anti-vascular endothelial growth factor (VEGF) agents is currently the firstline treatment for neovascular age-related macular degeneration (AMD), and these agents have shown vision-improving effects in pivotal trials.(1,2) However, there is a subgroup of patients who never become fluid-…”
BackgroundMonés, J., Leiva, M., Peña, M. T., Martínez, G., Biarnés, M., Garcia, M., Serrano, A., & Fernández, E. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.16-19355 · Cited by 51
Therapeutic aptamers in discovery, preclinical and clinical stages
Ismail, S. I., & Alshaer, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.006 · Cited by 54
Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion
Wroblewski, J. J., Wells, J. A., & Gonzales, C. R. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.08.005 · Cited by 50
The Antiangiogenic Effects of Integrin α5β1 Inhibitor (ATN-161) In Vitro and In Vivo
Wang, W., Wang, F., Lu, F., Xu, S., Hu, W., Huang, J., Gu, Q., & Sun, X. (2011) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.10-7097 · Cited by 51
Seguin‐Greenstein, S., Lightman, S., & Tomkins‐Netzer, O. (2016) · Journal of Ophthalmology · doi:10.1155/2016/4095852 · Cited by 53
Khurana, R. N., Li, C. H., & Lum, F. (2023) · Ophthalmology · doi:10.1016/j.ophtha.2023.02.021 · Cited by 52
Chae, B., Jung, J. J., Mrejen, S., Gallego‐Pinazo, R., Yannuzzi, N. A., PATEL, S. N., Chen, C. Y., Marsiglia, M., Boddu, S., & Freund, K. B. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16494 · Cited by 53
Gillies, M. C., Walton, R., Arnold, J., McAllister, I. L., Simpson, J. M., Hunyor, A. P., Guymer, R. H., Essex, R. W., Morlet, N., & Barthelmes, D. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.09.050 · Cited by 50
Frennesson, C. I., Nilsson, U., Peebo, B. B., & Nilsson, S. E. G. (2009) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2009.01576.x · Cited by 49
Cost Effectiveness of Treatments for Wet Age-Related Macular Degeneration
Mitchell, P., Annemans, L., White, R., Gallagher, M., & Thomas, S. K. (2011) · PharmacoEconomics · doi:10.2165/11585520-000000000-00000 · Cited by 57
“However, mean visual acuity of patients treated using the PIER regimen is not improved from baseline after 12 months of treatment, whereas mean visual acuity is increased using the MARINA or ANCHOR regimens.([8,9,42]) Finding a dosing regimen that maintains the high level of efficacy seen in the MARINA and ANCHOR stud…”
BackgroundMethodInfluentialHeussen, F. M., Shao, Q., Ouyang, Y., Joussen, A. M., & Müller, B. (2013) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-013-2553-7 · Cited by 53
Controlled release of therapeutic antibody formats
Schweizer, D., Serno, T., & Göpferich, A. M. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.08.001 · Cited by 56
Park, S. J., Oh, J., Kim, Y., Park, J.-H., Park, J. Y., Hong, H. K., Park, K. H., Lee, J.-W., Kim, H., Chung, J., et al. (2015) · Eye · doi:10.1038/eye.2014.329 · Cited by 51
Friberg, T. R., Tolentino, M., & for the LEVEL Study Group (2010) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.174946 · Cited by 50
“This development, the culmination of more than a decade of work into the pathophysiology of NV-AMD, led to the approval of two drugs as intravitreal therapies: pegaptanib sodium, an RNA aptamer targeting VEGF165,(1) and ranibizumab, a monoclonal antibody fragment that binds all VEGF isoforms.(2) 3 In addition, bevaciz…”
Lambìase, A., Coassin, M., Tirassa, P., Mantelli, F., & Aloe, L. (2009) · Annali dell Istituto Superiore di Sanità · doi:10.1590/s0021-25712009000400014 · Cited by 49
“In the last few years, treatment with repeated intravitreal injections of anti-angiogenic compounds has also been proposed, with substantial success in reducing progression of disease [16, 17].”
BackgroundChalam, K. V., Grover, S., Sambhav, K., Balaiya, S., & Murthy, R. K. (2014) · Journal of Ophthalmology · doi:10.1155/2014/502174 · Cited by 48
Ocular Infection: Endophthalmitis
Schwartz, S. G., Flynn, H. W., Das, T., & Mieler, W. F. (2015) · Developments in ophthalmology · doi:10.1159/000431195 · Cited by 51
Interleukin-18 Induces Retinal Pigment Epithelium Degeneration in Mice
Ijima, R., Kaneko, H., Ye, F., Nagasaka, Y., Takayama, K., Kataoka, K., Kachi, S., Iwase, T., & Terasaki, H. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15367 · Cited by 50
Liu, L., Xu, Y., Huang, Z., & Wang, X. (2016) · BMC Ophthalmology · doi:10.1186/s12886-016-0248-7 · Cited by 49
“Ranibizumab (Lucentis), the Fab fragment of recombinant humanized IgG1kmurine monoclonal antibody against VEGF-A, was approved for the treatment of ocular neovascular diseases such as wet agerelated macular degeneration [7, 8].”
BackgroundMantel, I., Gillies, M. C., & Souied, E. H. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.02.004 · Cited by 52
Carrasco, J., Pietsch, G.-A., Nicolas, M.-P., Koerber, C., Bennison, C., & Yoon, J. (2019) · Advances in Therapy · doi:10.1007/s12325-019-01147-6 · Cited by 53
Treatment of retinal diseases with VEGF antagonists
Schlingemann, R. O., & Witmer, A. N. (2009) · Progress in brain research · doi:10.1016/s0079-6123(09)17517-9 · Cited by 55
Remission and Dropout Rate of Anti-VEGF Therapy for Age-Related Macular Degeneration
Oishi, A., Mandai, M., Nishida, A., Hata, M., Matsuki, T., & Kurimoto, Y. (2011) · European Journal of Ophthalmology · doi:10.5301/ejo.2011.7430 · Cited by 53
“The pivotal trials had several exclusion criteria (1, 2) and some authors es-”
BackgroundAttenuation of Choroidal Neovascularization by β2-Adrenoreceptor Antagonism
Lavine, J. A., Sang, Y., Wang, S., Ip, M. S., & Sheibani, N. (2013) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2013.1476 · Cited by 49
Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration
Lai, T. Y. Y., Chan, W., Liu, D. T., & Lam, D. S. C. (2007) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0679-1 · Cited by 49
Current and emerging therapies for the treatment of age-related macular degeneration
Lauer, A. K. (2008) · Clinical ophthalmology · doi:10.2147/opth.s1485 · Cited by 56
“At 1 year, ANCHOR demonstrated a mean gain of 8.5 letters (0.3 mg group) to 11.3 letters (0.5 mg group) for patients treated with monthly ranibizumab injections compared to a mean loss of 9.5 letters for patients treated with verteporfi n every 3 months (Brown et al 2006).”
InfluentialNork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.210 · Cited by 48
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update
Parravano, M., Costanzo, E., Scondotto, G., Trifirò, G., & Virgili, G. (2021) · BioDrugs · doi:10.1007/s40259-021-00499-2 · Cited by 52
STEPIEN, K. E., ROSENFELD, P. J., PULIAFITO, C. A., FEUER, W., SHI, W., AL-ATTAR, L., DUBOVY, S. R., MURRAY, T. G., DAVIS, J. L., LEE, W.-H., et al. (2009) · Retina · doi:10.1097/iae.0b013e3181b1bb06 · Cited by 48
Cumbie, B. C., & Hermayer, K. L. (2007) · PubMed Central · Cited by 60
Ho, A. C., Albini, T. A., Brown, D. M., Boyer, D. S., Regillo, C. D., & Heier, J. S. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.5314 · Cited by 52
Self-citationShalchi, Z., Okada, M., Whiting, C., & HAMILTON, R. D. (2017) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2017.02.006 · Cited by 51
Berkowitz, S. T., Sternberg, P., Feng, X., Chen, Q., & Patel, S. N. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.1971 · Cited by 49
Management and Outcomes for Neovascular Age-Related Macular Degeneration
Kiss, S., Campbell, J. H., Almony, A., Shih, V., Serbin, M., LaPrise, A., & Wykoff, C. C. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.02.027 · Cited by 50
Iatrogenic ophthalmic artery occlusion and retinal artery occlusion
Lee, J. S., Kim, J. Y., Jung, C., & Woo, S. J. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100848 · Cited by 50
Christen, W. G., Cook, N. R., Manson, J. E., Buring, J. E., Chasman, D. I., Lee, I.-M. M., Bubes, V. Y., Li, C., Haubourg, M., & Schaumberg, D. A. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.4409 · Cited by 52
TNF‐α signaling regulates RUNX1 function in endothelial cells
Whitmore, H. A. B., Amarnani, D., O’Hare, M., Delgado‐Tirado, S., González-Buendía, L., An, M. B., Pedron, J., Bushweller, J. H., Arboleda‐Velásquez, J. F., & Kim, L. A. (2020) · The FASEB Journal · doi:10.1096/fj.202001668r · Cited by 48
Cardiovascular Risk and Antiangiogenic Therapy for Age-related Macular Degeneration
Tuñón, J., Ruiz‐Moreno, J. M., Martín-Ventura, J. L., Blanco‐Colio, L. M., Lorenzo, Ó., & Egido, J. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.02.003 · Cited by 55
Loewenstein, A., Ferencz, J. R., Lang, Y., Yeshurun, I., Pollack, A., Siegal, R., Lifshitz, T., Karp, J. S., Roth, D. B., Bronner, G., et al. (2010) · Retina · doi:10.1097/iae.0b013e3181d1a75e · Cited by 48
Self-citationAge-related macular degeneration and recent developments: new hope for old eyes?
Morris, B., Imrie, F., Armbrecht, A.-M., & Dhillon, B. (2007) · Postgraduate Medical Journal · doi:10.1136/pgmj.2006.052944 · Cited by 48
Pegaptanib sodium for the treatment of age-related macular degeneration
Apte, R. S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.3.499 · Cited by 52
The Royal College of Ophthalmologists Guidelines on AMD: Executive Summary
AMD Guidelines Group, Chakravarthy, U., & Williams, M. (2013) · Eye · doi:10.1038/eye.2013.233 · Cited by 47
Prolonged blockade of VEGF receptors does not damage retinal photoreceptors or ganglion cells
Miki, A., Miki, K., Ueno, S., Wersinger, D. M. B., Berlinicke, C., Shaw, G. C., Usui, S., Wang, Y., Zack, D. J., & Campochiaro, P. A. (2010) · Journal of Cellular Physiology · doi:10.1002/jcp.22129 · Cited by 47
“…of ranibizumab, an Fab that binds all isoforms of VEGF-A, causes significant improvement of 3 or more lines of visual acuity in 34–40% of patients with neovascular age-related macular degeneration (AMD), with a mean improvement of eight letters (Brown et al., 2006; Rosenfeld et al., 2006).”
BackgroundHow to overcome retinal neuropathy: The fight against angiogenesisrelated blindness
Jo, D. H., Kim, J. H., & Kim, J. H. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1007-6 · Cited by 49
“The roles of cytokines and growth factors besides VEGF in angiogenesis-related blindness Other growth factors besides VEGF have received interest because VEGF inhibition can only lead to attenuation of new vessel growth, not regression of neovascularization (Brown et al., 2006; Tolentino, 2009).”
Siedlecki, J., Wertheimer, C. M., Wolf, A., Liegl, R. G.-H., Priglinger, C., Priglinger, S. G., & Eibl-Lindner, K. H. (2017) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-017-3595-z · Cited by 51
Tzameret, A., Ketter-Katz, H., Edelshtain, V., Sher, I., Corem‐Salkmon, E., Levy, I., Last, D., Guez, D., Mardor, Y., Margel, S., et al. (2019) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0438-y · Cited by 49
Preferred therapies for neovascular age-related macular degeneration
Lally, D. R., Gerstenblith, A. T., & Regillo, C. D. (2012) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e328352411c · Cited by 47
The As-Needed Treatment Strategy for Choroidal Neovascularization: A Feedback-Based Treatment System
Spaide, R. F. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.04.010 · Cited by 47
Combined Intravitreal Ranibizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation
Lee, M. Y., Kim, K. S., & Lee, W. K. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.028 · Cited by 47
Droho, S., Thomson, B. R., Makinde, H. M., Cuda, C. M., Perlman, H., & Lavine, J. A. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02010-0 · Cited by 51
Nair, A. A., Finn, A. P., & Sternberg, P. W. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s368963 · Cited by 52
Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration
Tamiya, R., Hata, M., Tanaka, A., Tsuchikawa, M., Ueda‐Arakawa, N., Tamura, H., Miyata, M., Takahashi, A., Kido, A., Muraoka, Y., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-48190-6 · Cited by 47
Review and update of intraocular therapy in noninfectious uveitis
Sallam, A. B., Taylor, S. R. J., & Lightman, S. (2011) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32834bbd68 · Cited by 46
The link between intravitreal antivascular endothelial growth factor injections and glaucoma
SooHoo, J. R., Seibold, L. K., & Kahook, M. Y. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000036 · Cited by 46
“(MARINA) and Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration (ANCHOR) trials also reported transient IOP increases after injection with study medications compared with control (sham injection and verteporfin, respectively) [26,27].”
BackgroundSchmucker, C., Ehlken, C., Hansen, L. L., Antes, G., Agostini, H. T., & Lelgemann, M. (2010) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3283386783 · Cited by 47
Gray Hyper-Reflective Subretinal Exudative Lesions in Exudative Age-Related Macular Degeneration
Orès, R., Puche, N., Querques, G., Blanco-Garavito, R., Merle, B. M. J., COSCAS, G. J., Oubraham, H., Semoun, O., & Souied, E. H. (2014) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2014.04.025 · Cited by 47
Mathew, R., Richardson, M., & Sivaprasad, S. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.11.003 · Cited by 46
Clinical Review: Update on Treatment of Inflammatory Macular Edema
Norel, A. O., & Rothová, A. (2010) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2010.509530 · Cited by 46
Hatz, K. B., & Prünte, C. F. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307299 · Cited by 48
Hu, H., Liu, Y., Wang, L., & Li, W. (2017) · PLoS ONE · doi:10.1371/journal.pone.0173716 · Cited by 48
Yoshimine, S., Ogawa, S., Horiguchi, H., Terao, M., Miyazaki, A., Matsumoto, K., Tsuneoka, H., Nakano, T., Masuda, Y., & Pestilli, F. (2018) · Brain Structure and Function · doi:10.1007/s00429-018-1702-5 · Cited by 48
Brynskov, T., Munch, I. C., Larsen, T. M., Erngaard, L., & Sørensen, T. L. (2019) · Acta Ophthalmologica · doi:10.1111/aos.14183 · Cited by 51
“Secondary outcome measures were (a) proportion of eyes with BCVA 70 letters (6/12) or better, the threshold for retaining a driver’s license in most countries, including Denmark (International Council of Ophthalmology (ICO) 2006) (b) proportion of eyes with BCVA 60 letters (6/18) or better, which is considered the thr…”
BackgroundMethodInfluentialMaruko, I., Ogasawara, M., Yamamoto, A., Itagaki, K., Hasegawa, T., Arakawa, H., Nakayama, M., Koizumi, H., Okada, A. A., Sekiryu, T., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.03.010 · Cited by 48
Trends in Real-World Neovascular AMD Treatment Outcomes in the UK
Mehta, H., Kim, L. N., Mathis, T., Zalmay, P., Ghanchi, F. D., Amoaku, W. M. K., & Kodjikian, L. (2020) · Clinical ophthalmology · doi:10.2147/opth.s275977 · Cited by 49
“1%, respectively.(50,51) In real-world studies, it is more common to report rates of endophthalmitis per injection rather than per patient, although both provide useful information.”
BackgroundResultAflibercept for the Treatment of Age-Related Macular Degeneration
Trichonas, G., & Kaiser, P. K. (2013) · Ophthalmology and Therapy · doi:10.1007/s40123-013-0015-2 · Cited by 48
“The MARINA study looked at minimally classic and occult CNV lesions comparing monthly ranibizumab to sham injections while the ANCHOR study evaluated monthly ranibizumab injections versus sham injections combined with verteporfin photodynamic therapy (PDT) in predominantly classic CNV due to AMD.”
BackgroundSelf-citationSmith, B. T., Dhalla, M. S., Shah, G. K., Blinder, K. J., Ryan, E. H., & Mittra, R. A. (2008) · Retina · doi:10.1097/iae.0b013e31816b316e · Cited by 46
Palanki, M. S. S., Akiyama, H., Campochiaro, P. A., Cao, J., Chow, C. P., Dellamary, L. A., Doukas, J., Fine, R., Gritzen, C., Hood, J. D., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7011276 · Cited by 46
Hernández, C., & Simó, R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.8.1209 · Cited by 52
Rowe, L. W., & Ciulla, T. A. (2024) · Genes · doi:10.3390/genes15060720 · Cited by 53
Current Approaches to the Management of Diabetic Retinopathy and Diabetic Macular Oedema
Boscia, F. (2010) · Drugs · doi:10.2165/11538130-000000000-00000 · Cited by 53
The development of encapsulated cell technologies as therapies for neurological and sensory diseases
Zanin, M., Pettingill, L. N., Harvey, A. R., Emerich, D., Thanos, C. G., & Shepherd, R. K. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.021 · Cited by 49
Gomi, F., Sawa, M., Tsujikawa, M., & Nishida, K. (2012) · Retina · doi:10.1097/iae.0b013e31825be87f · Cited by 47
Age-related macular degeneration: Current and novel therapies
Prasad, P. S., Schwartz, S. D., & Hubschman, J. (2010) · Maturitas · doi:10.1016/j.maturitas.2010.02.006 · Cited by 46
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.